MINCI MOODY: Open Payments
NPI 1083378343 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,586 in 52 payments from 13 companies in 2025. Trend: 2023 $922 · 2024 $634 · 2025 $1,586
Food & beverage: $1,586
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $674 |
| Axsome Therapeutics, Inc. | 12 | $355 |
| E.R. Squibb & Sons, L.L.C. | 9 | $197 |
| Teva Pharmaceuticals USA, Inc. | 2 | $60 |
| Neurocrine BioSciences, Inc. | 2 | $58 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $56 |
| Supernus Pharmaceuticals, Inc. | 2 | $45 |
| ViiV Healthcare Company | 1 | $28 |
| Lundbeck LLC | 1 | $27 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $24 |
Products named: VRAYLAR, Auvelity, COBENFY, UZEDY, INGREZZA, CAPLYTA, Qelbree, DOVATO.
Industry payments across CA — which companies pay providers there.
